BlueWillow Biologics
Chemicals & Related Products · Michigan, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2311 Green Rd Ste A, Ann Arbor, Michigan...Phone Number
(734) 302-4000Website
www.bluewillow.comRevenue
$7.3 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About BlueWillow Biologics
BlueWillow Biologics specializes in the development of intranasal vaccines using their innovative NanoVax technology, which features a unique oil-in-water adjuvant. Their platform is designed to enhance the prevention and treatment of infectious diseases, demonstrating safety and effectiveness through successful human clinical trials. The company targets a wide range of viral, bacterial, and food antigens, aiming to provide robust immune responses for pandemic preparedness. BlueWillow Biologics is focused on advancing their clinical-stage technology to improve public health outcomes.Explore more
BlueWillow Biologics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BlueWillow Biologics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when BlueWillow Biologics launches new products
Earning: See what the market has to say on BlueWillow Biologics recently announced quarterly report
Check if BlueWillow Biologics has recently received funding, and reach out quickly before it becomes old news!
Check out if BlueWillow Biologics is spiking on competitors!
Click to see if BlueWillow Biologics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once BlueWillow Biologics has new funding data
BlueWillow Biologics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BlueWillow Biologics
Recommended Actions
Find VP level buyers at BlueWillow Biologics
Find 2 more new buyers
Compare Similar Companies to BlueWillow Biologics
Compare insights from companies similar to BlueWillow Biologics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BlueWillow Biologics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
BlueWillow Biologics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about BlueWillow Biologics.
BlueWillow Biologics financials insights
Gather financial insights about BlueWillow Biologics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Series A
$11M
BlueWillow Biologics Tech Stack
A closer look at the technologies used by BlueWillow Biologics
BlueWillow Biologics News & Media
BlueWillow Biologics to Present Significant Progress on Its Novel Intranasal Vaccine Technology at World Vaccine Congress Europe
Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparedness Presentation will demonstrate safety and immunogenicity, provide an update on NIH-funded bird flu trial, and highlight the technology’s potential in pandemic preparednessBlueWillow Biologics and Medigen Vaccine Biologics Announce Positive Results for Intranasal COVID-19 Booster Candidate in Pre-clinical Studies
ANN ARBOR, Mich. & TAIPEI, Taiwan--(BUSINESS WIRE)--BlueWillow Biologics, Inc., a pioneer in intranasal vaccine development, and Medigen Vaccine Biologics Corporation (MVC) (TPEx: 6547.TWO), a biopharmaceutical company focusing on the development and production of vaccines and biologics, today announced that its intranasal COVID-19 booster (BW-1019) provided protection and boosted immune response when administered following an intramuscular vaccine series in preclinical studies. The study examiBlueWillow Biologics to Present During BARDA Industry Day 2021
ANN ARBOR, Mich.--(BUSINESS WIRE)--BlueWillow Biologics, Inc. today announced that the company will present positive interim data from its phase 1 clinical trial of a novel intranasal anthrax vaccine at a Lightning Talks Session of BARDA’s Industry Day, November 3 and 4, 2021. BlueWillow’s rPA/NE01 anthrax vaccine, BW-1010, developed in collaboration with Porton Biopharma Limited (UK) and funded by the National Institute of Allergy and Infectious Diseases, is an intranasal recombinant protein vBlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board
ANN ARBOR, Mich.--(BUSINESS WIRE)--BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs. The members of the BlueWillow Biologics SAB include: Robin Isaacs, M.D. – Dr. Isaacs was Chief Medical Officer of Entasis The
Read more news
Top Chemicals & Related Products Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BlueWillow Biologics
Sign Up For FreeTo access detailed company insights
BlueWillow Biologics specializes in the development of intranasal vaccines using their innovative NanoVax technology, which features a unique oil-in-water adjuvant. Their platform is designed to enhance the prevention and treatment of infectious diseases, demonstrating safety and effectiveness through successful human clinical trials. The company t... Read More
